echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Arkuda develops potential 'first-in-class' therapy for common Alzheimer's disease

    Arkuda develops potential 'first-in-class' therapy for common Alzheimer's disease

    • Last Update: 2022-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Today, Arkuda Therapeutics announced the completion of a $64 million Series B financing


    Arkuda is working to develop a small molecule therapy that modulates progranulin, which plays an important role in lysosomal function and innate immunity in the brain


    Image source: Arkuda's official website

    The company also plans to explore the efficacy of these compounds in a variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease


    References:

    [1] Lilly, Pfizer-backed Arkuda bags $64M to test drug in frontotemporal dementia in 2023.


    [2] ARKUDA THERAPEUTICS RAISES $64 MILLION SERIES B FINANCING TO ADVANCE PIPELINE OF PROGRAMS TARGETING LYSOSOMAL BIOLOGY TO TREAT NEURODEGENERATIVE DISEASES.


    (Original abridged)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.